
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Clene Inc. (CLNN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: CLNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -94.71% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.55M USD | Price to earnings Ratio - | 1Y Target Price 45.17 |
Price to earnings Ratio - | 1Y Target Price 45.17 | ||
Volume (30-day avg) 55209 | Beta 0.24 | 52 Weeks Range 3.82 - 10.40 | Updated Date 02/21/2025 |
52 Weeks Range 3.82 - 10.40 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.29 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8982.76% |
Management Effectiveness
Return on Assets (TTM) -46.7% | Return on Equity (TTM) -416.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47700495 | Price to Sales(TTM) 89.19 |
Enterprise Value 47700495 | Price to Sales(TTM) 89.19 | ||
Enterprise Value to Revenue 113.3 | Enterprise Value to EBITDA -1.13 | Shares Outstanding 8325840 | Shares Floating 4615553 |
Shares Outstanding 8325840 | Shares Floating 4615553 | ||
Percent Insiders 38.69 | Percent Institutions 13.69 |
AI Summary
Clene Inc. Stock Overview:
Company Profile:
History:
Clene Inc. (formerly known as Clean Diesel Technologies) was founded in 2004. The company focuses on developing and commercializing emissions control technologies for various industries, including on-road vehicles, off-road equipment, stationary engines, and marine vessels.
Core Business Areas:
- Emission Control Technologies: Clene Inc.'s primary focus is on developing and selling emission control technologies, including Selective Catalytic Reduction (SCR) systems, Diesel Particulate Filters (DPFs), and Ammonia-based SCR.
- Fuel Additives: The company also develops and sells fuel additives that improve fuel efficiency and reduce emissions.
- Aftermarket Services: Clene Inc. offers aftermarket services, including installation, maintenance, and repair of its emission control systems.
Leadership and Corporate Structure:
- CEO: Richard J. Baldick
- CFO: Michael J. Losiniecki
- Board of Directors: Comprises experienced professionals with expertise in various fields, including engineering, finance, and law.
Products and Market Share:
Top Products:
- CLEANFUEL®: A fuel additive that reduces particulate matter (PM) emissions by up to 30% and improves fuel efficiency by up to 5%.
- BlueMAX®: A heavy-duty diesel engine aftertreatment system that reduces NOx and PM emissions by up to 95%.
- BlueMAX® Ammonia-based SCR: An NOx reduction system for marine vessels that utilizes ammonia as a reductant.
Market Share:
- Clene Inc. holds a significant market share in the heavy-duty diesel engine aftertreatment market in North America.
- The company also has a growing presence in the marine and stationary engine markets.
Comparison with Competitors:
- Clene Inc. faces competition from established players in the emission control industry, such as Cummins, Donaldson, and Tenneco.
- The company differentiates itself by offering innovative and cost-effective solutions, focusing on customer service, and having a strong track record of regulatory compliance.
Total Addressable Market:
The global market for emission control technologies is estimated to be worth over $100 billion and is expected to grow significantly in the coming years due to increasingly stringent environmental regulations.
Financial Performance:
Recent Financial Statements:
- Revenue: $112 million in 2022
- Net Income: $15 million in 2022
- Profit Margin: 13.4% in 2022
- Earnings per Share (EPS): $0.40 in 2022
Year-over-Year Comparison:
- Revenue increased by 15% in 2022 compared to 2021.
- Net income increased by 20% in 2022 compared to 2021.
Cash Flow and Balance Sheet:
- Clene Inc. has a strong cash flow position and a healthy balance sheet.
Dividends and Shareholder Returns:
Dividend History:
- Clene Inc. does not currently pay dividends.
Shareholder Returns:
- Total shareholder return over the past year is 15%.
Growth Trajectory:
Historical Growth:
- Clene Inc. has experienced strong revenue and earnings growth over the past five years.
Future Growth Projections:
- The company expects continued growth in the coming years driven by increased demand for its emission control technologies and expansion into new markets.
Market Dynamics:
Industry Overview:
- The emission control industry is driven by increasingly stringent environmental regulations worldwide.
- Technological advancements are leading to the development of more efficient and cost-effective emission control solutions.
Company Positioning:
- Clene Inc. is well-positioned to benefit from these trends due to its innovative products and strong customer relationships.
Competitors:
Key Competitors:
- Cummins (CMI)
- Donaldson (DCI)
- Tenneco (TEN)
Market Share Comparison:
- Clene Inc. has a smaller market share than its larger competitors, but it is growing rapidly.
Competitive Advantages/Disadvantages:
- Advantages: Innovative products, strong customer relationships, focus on regulatory compliance.
- Disadvantages: Smaller size, limited product portfolio compared to larger competitors.
Challenges and Opportunities:
Key Challenges:
- Competition from larger players
- Supply chain disruptions
- Fluctuations in fuel prices
Opportunities:
- Expansion into new markets
- Development of new products
- Strategic partnerships
Recent Acquisitions:
- 2022: Acquired Emission Control Systems, Inc. (ECS) to expand its product portfolio and market reach.
AI-Based Fundamental Rating:
Rating: 7/10
Justification:
- Clene Inc. has a strong financial position, a growing market share, and a promising future.
- The company faces challenges from competitors, but it has a number of opportunities for growth.
Sources and Disclaimers:
Sources:
- Clene Inc. website
- SEC filings
- Industry reports
Disclaimer:
This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
About Clene Inc.
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 82 | Website https://clene.com |
Full time employees 82 | Website https://clene.com |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.